Home » Topics » Science » New compound

New compound
RSS

Protein farnesyltransferase inhibitor from Banyu and Merck & Co.

May 31, 1996

Potential hypoxic marker synthesized by Evanston Hospital

May 31, 1996

OC104-26 identified as multidrug resistance (MDR)-reversing agent

May 31, 1996

ISIS-7597, an antisense oligonucleotide, shows promise in battling multidrug resistance

May 31, 1996

A highly lipophilic delta7-PGAI analogue, TEI-9826, demonstrates antitumor activity

May 31, 1996

Ligand reveals RXR-selective retinoid

May 31, 1996

MF-13 revealed as a selective tumor apoptosis-inducing agent

May 31, 1996

NSC-652287D shows important antitumor activity

May 31, 1996

Ciba-Geigy describes CGP-59326, a powerful antitumor agent

May 31, 1996

University of Pittsburgh research reveals GGTI-298, a new geranylgeranyltransferase-1 inhibitor

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...